Physician profile
Onyale Warnock
NPI 1952038903
$2,427.14
in general payments reported to CMS, 2019-2025
14 companies · $932 in 2025
The $932 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $170 · 2023: $293 · 2024: $1,032 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,256.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $779.83 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $264.97 | 2024-2025 | |
| Amgen INC. | $251.96 | 2024-2025 | Tepezza |
| Abbvie INC. | $221.68 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $196.45 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $177.98 | 2023-2025 | |
| Oyster Point Pharma, INC. | $158.44 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Ocular Therapeutix, INC. | $100.00 | 2022 | |
| Alcon Vision LLC | $85.00 | 2024-2025 | Tryptyr, Total30, Rocklatan |
| Astellas Pharma US INC | $82.63 | 2023 | |
| Harrow Eye, LLC | $43.25 | 2024 | Vevye |
| Dompe US, INC. | $25.46 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $21.57 | 2023 | Acuvue |
| Rxsight INC | $17.92 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Onyale Warnock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.